Developments TG Therapeutics reports positive topline results from 2 Phase 3 MS trials TG Therapeutics (NASDAQ:TGTX) reported positive topline data from its two Phase 3 trials evaluating ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (MS)... December 10, 2020